(:ENDP)
Business Focus: N/A
Sep 21, 2023 07:45 am ET
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
DUBLIN, Sept. 21, 2023 /CNW/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual scientific meeting. The meeting is taking place through September 23 in Louisville, Kentucky.
Sep 21, 2023 07:45 am ET
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual scientific meeting. The meeting is taking place through September 23 in Louisville, Kentucky.
Aug 08, 2023 07:45 am ET
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS
DUBLIN, Aug. 8, 2023 /CNW/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023.
Jun 12, 2023 07:30 am ET
Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
The ready-to-use pre-filled syringe combines two well-known, FDA-approved products in a standard concentration ratio Product eliminates the need for two discrete syringe preparations and administrations, which helps increase efficiency for hospitals and healthcare providersDUBLIN, June 12, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S.
Jun 12, 2023 07:30 am ET
Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
The ready-to-use pre-filled syringe combines two well-known, FDA-approved products in a standard concentration ratio Product eliminates the need for two discrete syringe preparations and administrations, which helps increase efficiency for hospitals and healthcare providersDUBLIN, June 12, 2023 /CNW/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S.
Apr 03, 2023 04:30 pm ET
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
DUBLIN, April 3, 2023 /CNW/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.
Apr 03, 2023 04:30 pm ET
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.
Aug 22, 2022 11:10 am ET
Thinking about buying stock in Mind Medicine, Endo International, Tilray, BioNano Genomics, or Nikola Corp?
NEW YORK, Aug. 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNMD, ENDP, TLRY, BNGO, and NKLA.
Aug 19, 2022 12:15 pm ET
Thinking about buying stock in Endo International, Vistagen Therapeutics, Applied DNA Sciences, Ford Motor, or Mobiquity Technologies?
NEW YORK, Aug. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, VTGN, APDN, F, and MOBQ.
Aug 18, 2022 10:45 am ET
Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical?
NEW YORK, Aug. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, FCEL, SAVA, CDAK, and TEVA.
Aug 17, 2022 12:37 pm ET
Thinking about buying stock in Endo International, T2 Biosystems, SoFi Technologies, Nu Holdings, or Bloom Energy?
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, TTOO, SOFI, NU, and BE.
Aug 16, 2022 10:00 pm ET
Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation
Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants
Aug 09, 2022 09:00 am ET
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
SK Biopharmaceuticals is eligible to receive milestones for future approval and commercialization in Canada and Israel
Aug 09, 2022 08:45 am ET
ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS
DUBLIN, Aug. 9, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022.
Aug 09, 2022 08:45 am ET
ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS
DUBLIN, Aug. 9, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022.
Aug 08, 2022 04:30 pm ET
Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy
MONTREAL, Aug. 8, 2022 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today that Health Canada has accepted its New Drug Submission (NDS) for cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. A decision from Health Canada as to whether cenobamate tablets can be marketed and sold in Canada under this NDS is expected mid-2023.
Aug 04, 2022 10:50 am ET
Thinking about buying stock in BioCryst Pharmaceuticals, Society Pass, Atlas Air Worldwide, SoFi Technologies, or Endo International?
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BCRX, SOPA, AAWW, SOFI, and ENDP.
Aug 03, 2022 10:50 am ET
Thinking about buying stock in Advanced Micro Devices, Endo International, Faraday Future Intelligent Electric, Robinhood Markets, or Rigel Pharmaceuticals?
NEW YORK, Aug. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, ENDP, FFIE, HOOD, and RIGL.
Jul 28, 2022 10:50 am ET
Thinking about buying stock in Ford Motor, Geovax Labs, Snap, Endo International, or Sundial Growers?
NEW YORK, July 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, GOVX, SNAP, ENDP, and SNDL.
Jul 15, 2022 08:30 am ET
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements
Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has entered into the License and Distribution Agreement and the Supply Agreement with Endo Ventures...
Jul 15, 2022 07:30 am ET
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
The product is under investigation for the treatment of Netherton syndrome, a rare disease
Jul 15, 2022 07:30 am ET
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
The product is under investigation for the treatment of Netherton syndrome, a rare disease
Jul 14, 2022 11:01 am ET
Thinking about buying stock in Shineco, Humanigen, Endo International, ContraFect, or Waitr?
NEW YORK, July 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SISI, HGEN, ENDP, CFRX, and WTRH.
Jul 13, 2022 10:55 am ET
Thinking about buying stock in Humanigen, Endo International, Kura Oncology, Delta Air Lines, or Clovis Oncology?
NEW YORK, July 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HGEN, ENDP, KURA, DAL, and CLVS.
Jul 12, 2022 10:50 am ET
Thinking about buying stock in American Airlines, Endo International, Versus Systems, Peloton Interactive, or Gap Inc?
NEW YORK, July 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, ENDP, VS, PTON, and GPS.
Jul 11, 2022 11:25 am ET
Thinking about buying stock in Mullen Automotive, Iterum Therapeutics, Endo International, Aditxt, or COMSovereign?
NEW YORK, July 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, ITRM, ENDP, ADTX, and COMS.
Jul 01, 2022 01:32 pm ET
Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
DUBLIN, July 1, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.
Jul 01, 2022 07:30 am ET
Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder
DUBLIN, July 1, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or "CCH") in participants with adhesive capsulitis (AC) of the shoulder, commonly known as "frozen shoulder." While Phase 2 study participants receiving up to three doses of CCH showed some improvement in the change from baseline in the adapted American Shoulder and Elbow Surgeons (ASES) Standardized Shoulder Form composite score for the affected shoulder at the Day 95 visit, the difference compared to those study participants re
Jun 28, 2022 01:10 pm ET
Thinking about buying stock in Endo International, Exela Technologies, Las Vegas Sands, Li Auto, or Boxed?
NEW YORK, June 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, XELA, LVS, LI, and BOXD.
Jun 21, 2022 10:59 am ET
Thinking about buying stock in Endo International, Mereo BioPharma, Revlon, American Airlines, or Li Auto?
NEW YORK, June 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, MREO, REV, AAL, and LI.
Jun 13, 2022 10:50 am ET
Thinking about buying stock in Endo International, American Airlines, Science 37, TDH Holdings, or Norwegian Cruise Line?
NEW YORK, June 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, AAL, SNCE, PETZ, and NCLH.
Jun 13, 2022 06:30 am ET
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
DUBLIN, June 13, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain.
Jun 13, 2022 06:30 am ET
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
DUBLIN, June 13, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain.
Jun 13, 2022 06:30 am ET
TLC Announces TLC599 Agreement with Endo
TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with Endo International plc (Nasdaq:...
Jun 09, 2022 08:00 am ET
National Survey of Over 1,500 Men Shows More Than Half Were Unsure of How to Improve Their Mental and Sexual Health; New Partnership Aims to Change That Through Education and Free Virtual Consultation
Endo, Vault Health, the Sexual Medicine Society of North America (SMSNA) and Men's Health Network (MHN) join forces to launch Healthy Now: A Men's Health Coalition™ to encourage men to make all aspects of their health—physical, mental and sexual—a priorityNew national survey underscores the need for and importance of the education and access to resources provided by this new programVisitHealthyNow.com offers information on physical, mental and sexual health issues and access to a free virtual consultation through Vault HealthDUBLIN, June 9, 2022 /CNW/ -- A recent survey of 1,517 U.S. men age
Jun 09, 2022 08:00 am ET
National Survey of Over 1,500 Men Shows More Than Half Were Unsure of How to Improve Their Mental and Sexual Health; New Partnership Aims to Change That Through Education and Free Virtual Consultation
Endo, Vault Health, the Sexual Medicine Society of North America (SMSNA) and Men's Health Network (MHN) join forces to launch Healthy Now: A Men's Health Coalition™ to encourage men to make all aspects of their health—physical, mental and sexual—a priorityNew national survey underscores the need for and importance of the education and access to resources provided by this new programVisitHealthyNow.com offers information on physical, mental and sexual health issues and access to a free virtual consultation through Vault HealthDUBLIN, June 9, 2022 /PRNewswire/ -- A recent survey of 1,517 U.S.
Jun 06, 2022 10:45 am ET
Thinking about buying stock in Mullen Automotive, VICI Properties, Trip.com, Praxis Precision Medicines, or Endo International?
NEW YORK, June 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, VICI, TCOM, PRAX, and ENDP.
Jun 03, 2022 07:21 pm ET
Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600
NEW YORK, June 3, 2022 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
Jun 01, 2022 11:00 am ET
Thinking about buying stock in Mullen Automotive, Endo International, AMC Entertainment, Tellurian, or Genocea Biosciences?
NEW YORK, June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, ENDP, AMC, TELL, and GNCA.
May 06, 2022 10:55 am ET
Thinking about buying stock in Vinco Ventures, Digital Brands, Endo, Clovis Oncology, or Under Armour?
NEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, DBGI, ENDP, CLVS, and UAA.
May 05, 2022 04:30 pm ET
ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS
DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance.
May 05, 2022 04:30 pm ET
ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS
DUBLIN, May 5, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance.
May 05, 2022 04:15 pm ET
Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting
DUBLIN, May 5, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. The design of the study will be featured during the annual Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary aesthetic medicine meeting, taking place in Nashville, TN, May 11-15, 2022.
May 05, 2022 04:15 pm ET
Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting
DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. The design of the study will be featured during the annual Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary aesthetic medicine meeting, taking place in Nashville, TN, May 11-15, 2022.
May 03, 2022 10:35 am ET
Thinking about buying stock in Lucid Group, Sesen Bio, Borqs Technologies, Endo International, or Spero Therapeutics?
NEW YORK, May 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, SESN, BRQS, ENDP, and SPRO.
May 02, 2022 07:55 am ET
Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
DUBLIN, May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.
May 02, 2022 07:55 am ET
Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
DUBLIN, May 2, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.
May 02, 2022 07:30 am ET
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited
Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced today that it...
Apr 28, 2022 07:30 am ET
Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe
Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced today that the U.S....
Apr 20, 2022 05:23 pm ET
Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo
DUBLIN, April 20, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals has reversed a trial court judge's order denying a motion for recusal by Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, Endo or the Company) in Clay County et al. v. Purdue Pharma, L.P., et al., (formerly known as Dunaway, et al. v. Purdue Pharma, L.P., et al.), pending in the Circuit Court for Cumberland County, Tennessee, and remanded the case for transfer to a different judge.
Apr 20, 2022 05:23 pm ET
Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo
DUBLIN, April 20, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals has reversed a trial court judge's order denying a motion for recusal by Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, Endo or the Company) in Clay County et al. v. Purdue Pharma, L.P., et al., (formerly known as Dunaway, et al. v. Purdue Pharma, L.P., et al.), pending in the Circuit Court for Cumberland County, Tennessee, and remanded the case for transfer to a different judge.
Apr 12, 2022 05:00 pm ET
Endo to Announce First-Quarter 2022 Financial Results
DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open.
Apr 12, 2022 05:00 pm ET
Endo to Announce First-Quarter 2022 Financial Results
DUBLIN, April 12, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open.
Mar 28, 2022 07:30 am ET
Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials
DUBLIN, March 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.
Mar 28, 2022 07:30 am ET
Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials
DUBLIN, March 28, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.
Mar 28, 2022 07:30 am ET
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate Injection (“Ephedrine”), a...
Mar 03, 2022 03:30 pm ET
Endo Launches New Living Our Values Program to Recognize Outstanding Team Members
DUBLIN, March 3, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program.
Mar 03, 2022 03:30 pm ET
Endo Launches New Living Our Values Program to Recognize Outstanding Team Members
DUBLIN, March 3, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program.
Mar 02, 2022 08:15 am ET
Butt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events
DUBLIN, March 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) has kicked off a series of more than 200 patient events that will be held across the United States as part of Butt First, a new direct-to-consumer awareness campaign designed to excite and educate women about Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes). QWO received FDA approval in July 2020 and is the first and only injectable treatment for moderate to severe cellulite in the buttocks of adult women. QWO is available in aesthetic practices across the country.
Feb 28, 2022 03:15 pm ET
ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS
DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.
Feb 28, 2022 03:15 pm ET
ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS
DUBLIN, Feb. 28, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.
Feb 11, 2022 06:30 am ET
Endo Comments on Default Judgment on Liability in Tennessee State Court
DUBLIN,, Feb. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it expects a Tennessee state court to issue an order granting plaintiffs' request for a default judgment on liability against Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, Endo or the Company) in Dunaway, et al. v. Purdue Pharma, L.P., et al., Case No. 2:19-CV-00038, pending in the Circuit Court for Cumberland County, Tennessee, as a sanction for alleged discovery improprieties in a different case. The Company's expectation is base
Feb 07, 2022 06:30 am ET
Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles
DUBLIN, Feb. 7, 2022 /PRNewswire/ --
Jan 25, 2022 04:00 pm ET
Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results
DUBLIN, Jan. 25, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S. financial markets open.
Jan 25, 2022 04:00 pm ET
Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results
DUBLIN, Jan. 25, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S. financial markets open.
Jan 18, 2022 06:00 am ET
Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
DUBLIN, Jan. 18, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Florida.
Jan 18, 2022 06:00 am ET
Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Florida.
Jan 17, 2022 06:30 am ET
Paladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in Canada
The new antibiotic treatment is for adult patients with acute bacterial skin and skin structure infections (ABSSSI)³
Jan 13, 2022 06:30 am ET
Jan 13, 2022 06:30 am ET
Jan 11, 2022 06:00 am ET
Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development
DUBLIN, Jan. 11, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S.
Jan 11, 2022 06:00 am ET
Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development
DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S.
Jan 10, 2022 06:30 am ET
Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold
DUBLIN, Jan. 10, 2022 /PRNewswire/ --
Jan 10, 2022 06:30 am ET
Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold
DUBLIN, Jan. 10, 2022 /CNW/ --
Jan 04, 2022 05:25 pm ET
Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
DUBLIN, Jan. 4, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
Jan 04, 2022 05:25 pm ET
Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
Jan 04, 2022 04:00 pm ET
Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference
DUBLIN, Jan. 4, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST.
Jan 04, 2022 04:00 pm ET
Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference
DUBLIN, Jan. 4, 2022 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST.
Dec 23, 2021 01:19 pm ET
Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims
DUBLIN, Dec. 23, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas.
Dec 23, 2021 01:19 pm ET
Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims
DUBLIN, Dec. 23, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas.
Dec 23, 2021 05:00 am ET
Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada
DUBLIN, Dec. 23, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of cenobamate on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada related to cenobamate.
Dec 23, 2021 05:00 am ET
Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada
DUBLIN, Dec. 23, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of cenobamate on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada related to cenobamate.
Dec 15, 2021 09:23 am ET
Endo Announces Favorable Final Ruling in California State Court Opioid Trial
DUBLIN, Dec. 15, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California trial court issuing a final ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI), are not liable.
Dec 15, 2021 09:23 am ET
Endo Announces Favorable Final Ruling in California State Court Opioid Trial
DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California trial court issuing a final ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI), are not liable.
Nov 22, 2021 09:53 am ET
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting
DUBLIN, Nov. 22, 2021 /CNW/ -- Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS).
Nov 22, 2021 09:53 am ET
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting
DUBLIN, Nov. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS).
Nov 22, 2021 08:00 am ET
Settlement Administrator Angeion Group Announces Proposed Class Action Settlement In Endo Securities Litigation
PHILADELPHIA, Nov. 22, 2021 /PRNewswire/ -- IF YOU PURCHASED OR ACQUIRED ENDO INTERNATIONAL, PLC ("ENDP") ORDINARY SHARES FROM MARCH 2, 2015 THROUGH FEBRUARY 27, 2017, INCLUSIVE (THE "CLASS"), YOU COULD RECEIVE A PAYMENT FROM A CLASS ACTION SETTLEMENT. CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE CLASS AS SET FORTH IN THE STIPULATION OF SETTLEMENT.
Nov 18, 2021 06:30 am ET
Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection
DUBLIN, Nov. 18, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par's calcitonin salmon injection is AP-rated to Viatris' MIACALCIN® and is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required. Calcitonin salmon injection is also used to treat postmeno
Nov 18, 2021 06:30 am ET
Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection
DUBLIN, Nov. 18, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par's calcitonin salmon injection is AP-rated to Viatris' MIACALCIN® and is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required. Calcitonin salmon injection is also used to treat p
Nov 17, 2021 06:30 am ET
Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines
Agreement to fund expansion of Rochester, MI facility to support fill-finish manufacturing of both mRNA and adenovirus vaccines
Nov 17, 2021 06:30 am ET
Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines
Agreement to fund expansion of Rochester, MI facility to support fill-finish manufacturing of both mRNA and adenovirus vaccines
Nov 08, 2021 06:30 am ET
Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care
DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT®, vasopressin injection, USP, vial presentations to healthcare providers through Premier's Premier ProRx® program, helping to maintain supply continuity for a medication needed in critical care, including some of the most acute cases of COVID-19.
Nov 08, 2021 06:30 am ET
Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care
DUBLIN, Nov. 8, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT®, vasopressin injection, USP, vial presentations to healthcare providers through Premier's Premier ProRx® program, helping to maintain supply continuity for a medication needed in critical care, including some of the most acute cases of COVID-19.
Nov 05, 2021 09:31 am ET
Thinking about buying stock in Ardelyx, Endo International, Phunware, Canada Goose Holdings, or Nikola Corp?
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARDX, ENDP, PHUN, GOOS, and NKLA.
Nov 04, 2021 04:15 pm ET
Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance
DUBLIN, Nov. 4, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021.
Nov 04, 2021 04:15 pm ET
Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance
DUBLIN, Nov. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021.
Nov 02, 2021 08:35 am ET
Thinking about buying stock in Sab Biotherapeutics, Artelo Biosciences, Under Armour, Endo International, or Teva Pharmaceutical?
NEW YORK, Nov. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SABS, ARTL, UAA, ENDP, and TEVA.
Nov 02, 2021 07:00 am ET
California State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial
DUBLIN, Nov. 2, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that, following a months-long trial, one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California state court tentatively ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc., are not liable.
Nov 02, 2021 07:00 am ET
California State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial
DUBLIN, Nov. 2, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that, following a months-long trial, one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California state court tentatively ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc., are not liable.
Oct 25, 2021 07:00 am ET
Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease
DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLEX as the first and only nonsurgical FDA-approved treatment for Peyronie's disease (PD) and encourages them to seek treatment if they believe they may have the condition, in which a buildup of fibrous scar tissue (plaque) causes a curvature of the penis.
Oct 22, 2021 09:31 am ET
Thinking about buying stock in Athira Pharma, Altimeter Growth, Seelos Therapeutics, Endo International, or Skillz?
NEW YORK, Oct. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHA, AGC, SEEL, ENDP, and SKLZ.
Oct 22, 2021 07:00 am ET
Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting
DUBLIN, Oct. 22, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.
Oct 22, 2021 07:00 am ET
Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting
DUBLIN, Oct. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.
Oct 05, 2021 05:00 pm ET
Endo to Announce Third Quarter 2021 Financial Results
DUBLIN, Oct. 5, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2021 financial results on November 4, 2021 and members of its senior management team will host a conference call and webcast on November 5, 2021 at 7:30am ET before the U.S. financial markets open.
Oct 05, 2021 05:00 pm ET
Endo to Announce Third Quarter 2021 Financial Results
DUBLIN, Oct. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2021 financial results on November 4, 2021 and members of its senior management team will host a conference call and webcast on November 5, 2021 at 7:30am ET before the U.S. financial markets open.
Sep 30, 2021 11:08 am ET
Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting
DUBLIN, Sept. 30, 2021 /PRNewswire/ --
Sep 30, 2021 11:08 am ET
Sep 28, 2021 01:59 pm ET
Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims
DUBLIN, Sept. 28, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has reached an agreement in principle with the Louisiana Attorney General's office to settle all opioid-related cases and claims of the state and other Louisiana governmental persons and entities in exchange for a total payment of $7.5 million. The settlement, including the payment, will be subject to 100% participation by Louisiana's political subdivisions (to be provided to Endo by October 28, 2021) and the execution of definitive documentation. The settlement will include no admission o
Sep 28, 2021 01:59 pm ET
Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims
DUBLIN, Sept. 28, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has reached an agreement in principle with the Louisiana Attorney General's office to settle all opioid-related cases and claims of the state and other Louisiana governmental persons and entities in exchange for a total payment of $7.5 million. The settlement, including the payment, will be subject to 100% participation by Louisiana's political subdivisions (to be provided to Endo by October 28, 2021) and the execution of definitive documentation. The settlement will include no admi
Sep 22, 2021 10:05 am ET
Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States
DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the generic version of Pfizer's Chantix® (varenicline), 0.5 mg and 1 mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
Sep 13, 2021 08:30 am ET
Thinking about buying stock in Leap Therapeutics, Aterian, Hepion Pharmaceuticals, Adaptimmune Therapeutics, or Endo International?
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTX, ATER, HEPA, ADAP, and ENDP.
Sep 10, 2021 08:35 am ET
Thinking about buying stock in IVERIC bio, T2 Biosystems, Endo International, Arbutus Biopharma, or Katapult?
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISEE, TTOO, ENDP, ABUS, and KPLT.
Sep 09, 2021 07:34 pm ET
Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation
DUBLIN, Sept. 9, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc., have settled three consolidated cases pending in Suffolk County Supreme Court in the State of New York: County of Suffolk v. Purdue Pharma L.P. et al., Case No. 400001/2017; County of Nassau v. Purdue Pharma L.P. et al., Case No. 400008/2017; and The State of New York v. Purdue Pharma L.P. et al., Case No. 400016/2018.
Sep 09, 2021 07:34 pm ET
Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation
DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc., have settled three consolidated cases pending in Suffolk County Supreme Court in the State of New York: County of Suffolk v. Purdue Pharma L.P. et al., Case No. 400001/2017; County of Nassau v. Purdue Pharma L.P. et al., Case No. 400008/2017; and The State of New York v. Purdue Pharma L.P. et al., Case No. 400016/2018.
Aug 31, 2021 02:09 pm ET
Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
DUBLIN, Aug. 31, 2021 /PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today commented on the United States District Court for the District of Delaware's non-infringement ruling in favor of Eagle Pharmaceuticals Inc. ("Eagle") in patent litigation regarding Eagle's abbreviated new drug application, or ANDA, for Par Sterile Products, LLC's VASOSTRICT® product. Because the court found non-infringement of Endo's patents by Eagle's proposed product, it did not rule on the patents' validity.
Aug 31, 2021 02:09 pm ET
Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
DUBLIN, Aug. 31, 2021 /CNW/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today commented on the United States District Court for the District of Delaware's non-infringement ruling in favor of Eagle Pharmaceuticals Inc. ("Eagle") in patent litigation regarding Eagle's abbreviated new drug application, or ANDA, for Par Sterile Products, LLC's VASOSTRICT® product. Because the court found non-infringement of Endo's patents by Eagle's proposed product, it did not rule on the patents' validity.
Aug 23, 2021 10:50 am ET
Thinking about buying stock in Endo International, Nio, New Oriental Education, Tencent Music Entertainment, or Senseonics?
NEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, NIO, EDU, TME, and SENS.
Aug 20, 2021 10:45 am ET
Thinking about buying stock in Sonnet BioTherapeutics, Progenity, Hexo Corp, SunLink Health Systems, or Endo International?
NEW YORK, Aug. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, PROG, HEXO, SSY, and ENDP.
Aug 05, 2021 04:15 pm ET
Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
DUBLIN, Aug. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2021.
Aug 05, 2021 04:15 pm ET
Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
DUBLIN, Aug. 5, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2021.
Aug 04, 2021 07:30 am ET
Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case
DUBLIN, Aug. 4, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, in the Circuit Court for Sullivan County, Tennessee.
Aug 04, 2021 07:30 am ET
Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case
DUBLIN, Aug. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, in the Circuit Court for Sullivan County, Tennessee.
Jul 29, 2021 09:00 am ET
Jul 29, 2021 09:00 am ET
Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting
DUBLIN, July 29, 2021 /PRNewswire/ --
Jul 22, 2021 12:33 pm ET
Endo Announces Agreement in Principle to Settle Tennessee State Court Case
DUBLIN, July 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have reached an agreement in principle to settle an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, in the Circuit Court for Sullivan County, Tennessee.
Jul 22, 2021 12:33 pm ET
Endo Announces Agreement in Principle to Settle Tennessee State Court Case
DUBLIN, July 22, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have reached an agreement in principle to settle an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, in the Circuit Court for Sullivan County, Tennessee.
Jul 22, 2021 10:51 am ET
Thinking about buying stock in Chembio Diagnostics, Cleveland-Cliffs, SoFi Technologies, FirstEnergy, or Endo Int?
NEW YORK, July 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, CLF, SOFI, FE, and ENDP.
Jul 21, 2021 09:31 am ET
Thinking about buying stock in Chembio Diagnostics, Endo, Aprea Therapeutics, RealReal, or Amplify Energy?
NEW YORK, July 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, ENDP, APRE, REAL, and AMPY.
Jul 15, 2021 06:56 pm ET
Endo Comments on Tennessee Appeals Court Orders
DUBLIN, July 15, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced the issuance of several orders by the Tennessee Supreme Court and the Tennessee Court of Appeals regarding a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al.
Jul 15, 2021 06:56 pm ET
Endo Comments on Tennessee Appeals Court Orders
DUBLIN, July 15, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the issuance of several orders by the Tennessee Supreme Court and the Tennessee Court of Appeals regarding a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al.
Jun 24, 2021 05:00 pm ET
Endo to Announce Second Quarter 2021 Financial Results
DUBLIN, June 24, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its second–quarter 2021 financial results on August 5, 2021 after the U.S. financial markets close and members of its senior management team will host a conference call and webcast on August 6, 2021 at 7:30am ET before the U.S. financial markets open.
Jun 24, 2021 05:00 pm ET
Endo to Announce Second Quarter 2021 Financial Results
DUBLIN, June 24, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its second–quarter 2021 financial results on August 5, 2021 after the U.S. financial markets close and members of its senior management team will host a conference call and webcast on August 6, 2021 at 7:30am ET before the U.S. financial markets open.
Jun 24, 2021 07:30 am ET
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021
DUBLIN, June 24, 2021 /CNW/ -- Endo International plc (NASDAQ:ENDP) announced today that data from studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during Cosmetic Bootcamp Summer Event.
Jun 24, 2021 07:30 am ET
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021
DUBLIN, June 24, 2021 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that data from studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during Cosmetic Bootcamp Summer Event.
Jun 11, 2021 06:51 pm ET
Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo
DUBLIN, June 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al.
Jun 11, 2021 06:51 pm ET
Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo
DUBLIN, June 11, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al.
Jun 09, 2021 07:00 am ET
Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada
MONTREAL, June 9, 2021 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), today announced Health Canada's approval of Wakix® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.
May 06, 2021 04:15 pm ET
Endo Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
DUBLIN, May 6, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2021.
May 03, 2021 06:00 am ET
Maverix Private Equity Announces Team Additions
TORONTO, May 3, 2021 /CNW/ - Maverix Private Equity, a Toronto-based private equity firm which recently announced an inaugural USD $500 million growth-fund, has today announced the addition of Michael Wasserman as a Managing Partner, joining Founder John Ruffolo and Mark Maybank. Michael is returning to Canada after 17 years at H.I.G Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management. Most recently, Michael was a Managing Director of H.I.G. BioHealth Partners, the firm's dedicated healthcare investment fund, where
Apr 29, 2021 07:30 am ET
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021
DUBLIN, April 29, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that data relevant to the use of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during The Aesthetic Meeting 2021.
Apr 27, 2021 04:15 pm ET
Endo Implements Board Succession Plan
Mark Barberio appointed Chairman of the Board of Directors effective at 2021 Annual General Meeting
Apr 13, 2021 05:00 pm ET
Endo to Announce First Quarter 2021 Financial Results
DUBLIN, April 13, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2021 financial results on May 6, 2021 and members of its senior management team will host a conference call and webcast on May 7, 2021 at 7:30am ET before the U.S. financial markets open.
Apr 13, 2021 04:15 pm ET
Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery
DUBLIN, April 13, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that Phase 3 data evaluating Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO.
Apr 12, 2021 07:00 am ET
ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada
DUBLIN and LONDON, April 12, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) and ADVANZ PHARMA Corp. Limited, a specialty pharmaceutical company with a strategic focus on complex medicines, are pleased to announce today that Endo International plc's subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sàrl entity, a subsidiary of ADVANZ PHARMA, to commercialize and distribute on an exclusive basis Xydalba® (dalbavancin hydrochloride) in Canada.
Apr 07, 2021 09:18 am ET
Endo Comments on Entry of Default Liability Judgment in Tennessee State Court Case
DUBLIN, April 7, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced the entry of an order granting a default judgment on liability against its wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI) in Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, which has been pending in the Circuit Court for Sullivan County at Kingsport, Tennessee since 2017.
Mar 11, 2021 05:35 pm ET
Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
DUBLIN, March 11, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") priced $1.295 billion aggregate principal amount of 6.125% senior secured notes due 2029 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $295.0 million over the previously contemplated offering amount. The notes will be senior secured obli
Mar 11, 2021 06:33 am ET
Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
DUBLIN, March 11, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. ("Endo Luxembourg") and Endo U.S. Inc. (together with Endo Luxembourg, the "Issuers") intend to offer senior secured notes, subject to market and customary conditions. The notes will be senior secured obligations of the Issuers and will be guaranteed by Endo and certain of Endo's subsidiaries and will be secured by first priority liens on the same collateral that secures Endo's obligations under its existing senior secure
Mar 04, 2021 06:30 am ET
Endo International plc Commences Refinancing of its Existing Term Loan
DUBLIN, March 4, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has commenced a refinancing of its existing $3.3 billion senior secured term loan due 2024 with the net proceeds of a new senior secured term loan and other debt issuances. The new term loan will have the same guarantees and collateral as Endo's existing credit agreement. The proposed transactions, if completed, are not expected to increase Endo's total indebtedness but would extend Endo's debt maturity profile and provide Endo with greater financial flexibility.
Feb 25, 2021 03:30 pm ET
Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
DUBLIN, Feb. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.
Feb 25, 2021 03:30 pm ET
Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
DUBLIN, Feb. 25, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.
Feb 17, 2021 04:00 pm ET
Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference
DUBLIN, Feb. 17, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on Monday, March 1, 2021 at 9:15 a.m. ET.
Feb 17, 2021 04:00 pm ET
Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference on Monday, March 1, 2021 at 9:15 a.m. ET.
Feb 17, 2021 03:15 pm ET
Endo Appoints Jennifer M. Chao to Board of Directors
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board. Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting.
Feb 17, 2021 03:15 pm ET
Endo Appoints Jennifer M. Chao to Board of Directors
DUBLIN, Feb. 17, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board. Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting.
Jan 26, 2021 04:00 pm ET
Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results
DUBLIN, Jan. 26, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2020 financial results on February 25, 2021 after the market closes and members of its senior management team will host a conference call and webcast on February 26, 2021 at 7:30am ET before the U.S. financial markets open.
Jan 26, 2021 04:00 pm ET
Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results
DUBLIN, Jan. 26, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2020 financial results on February 25, 2021 after the market closes and members of its senior management team will host a conference call and webcast on February 26, 2021 at 7:30am ET before the U.S. financial markets open.
Jan 05, 2021 08:15 am ET
Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), to register,...
Jan 05, 2021 07:36 am ET
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the agreement, Endo obtained the rights to abaloparatide-subcutaneous injection (abaloparatide-SC) and abaloparatide-transdermal patch (abaloparatide-TD), a novel for
Jan 05, 2021 07:36 am ET
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
DUBLIN, Jan. 5, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the agreement, Endo obtained the rights to abaloparatide-subcutaneous injection (abaloparatide-SC) and abaloparatide-transdermal patch (abaloparatide-TD), a novel formulatio
Jan 05, 2021 07:00 am ET
Endo Aesthetics Launches "Really Cellulite" Campaign
DUBLIN and MALVERN, Pa., Jan. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiary, Endo Aesthetics LLC, launched an unbranded campaign designed to eliminate the shame and misinformation relating to cellulite. Together, these issues have precipitated a lengthy list of temporary "solutions" that range from diet and exercise to various lotions, creams and scrubs that only add to women's skepticism of cellulite treatment. The vibrant and innovative Really Cellulite campaign will be shared with consumers via social media, influencer content, paid digi
Jan 04, 2021 08:00 am ET
Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States
DUBLIN, Jan. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules.
Jan 04, 2021 08:00 am ET
Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States
DUBLIN, Jan. 4, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza® (lubiprostone) 8 mcg and 24 mcg capsules.
Dec 18, 2020 04:00 pm ET
Endo to Participate at J.P. Morgan 39th Annual Healthcare Conference
DUBLIN, Dec. 18, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. EST.
Dec 18, 2020 04:00 pm ET
Endo to Participate at J.P. Morgan 39th Annual Healthcare Conference
DUBLIN, Dec. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. EST.
Dec 02, 2020 08:09 am ET
BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals
WILMINGTON, Del., Dec. 2, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the successful completion of its acquisition by Endo International plc (Endo) for approximately $658.2 million in equity value.
Dec 02, 2020 07:45 am ET
Endo Completes Acquisition of BioSpecifics
DUBLIN, Dec. 2, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired).
Dec 02, 2020 07:45 am ET
Endo Completes Acquisition of BioSpecifics
DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired).
Nov 18, 2020 04:00 pm ET
Endo to Participate In Upcoming Investor Conferences
DUBLIN, Nov. 18, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that the Company will participate in two investor conferences.
Nov 18, 2020 04:00 pm ET
Endo to Participate In Upcoming Investor Conferences
DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that the Company will participate in two investor conferences.
Nov 18, 2020 07:00 am ET
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
DUBLIN, Nov. 18, 2020 /CNW/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price"), net
Nov 18, 2020 07:00 am ET
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price
Nov 10, 2020 05:46 pm ET
Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GM: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be...
Nov 06, 2020 12:26 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
WILMINGTON, Del., Nov. 6, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. ("BioSpecifics") (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics' agreement to be acquired by Endo International plc (NASDAQ GS: ENDP). Under the terms of the agreement, BioSpecifics' shareholders will receive $88.50 per share in cash.
Nov 05, 2020 03:49 pm ET
Endo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2020.
Nov 05, 2020 03:49 pm ET
Endo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance
DUBLIN, Nov. 5, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2020.
Nov 05, 2020 06:30 am ET
Endo Announces Strategic Actions to Further Position the Company for Long-Term Success
- Initiatives to Enable Company to Reinvest in Key Areas of Growth -
Nov 05, 2020 06:30 am ET
Endo Announces Strategic Actions to Further Position the Company for Long-Term Success
- Initiatives to Enable Company to Reinvest in Key Areas of Growth -
Nov 02, 2020 06:00 am ET
Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer is being made pursuant to the Agreement and Plan o
Nov 02, 2020 06:00 am ET
Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.
DUBLIN, Nov. 2, 2020 /CNW/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merge
Oct 22, 2020 04:30 pm ET
Envarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan
MONTREAL, Oct. 22, 2020 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today that Ontario, Quebec, Manitoba and Saskatchewan now cover the cost of Envarsus® PA for kidney and liver transplant adult patients who meet certain reimbursement criteria (see below) for the prophylaxis of organ rejection. This announcement follows an agreement signed in July between Paladin Labs and the pan-Canadian Pharmaceuticals Alliance (pCPA) on the terms of public reimbursement for Envarsus® PA.
Oct 22, 2020 07:00 am ET
Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a...
Oct 19, 2020 01:50 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioSpecifics Technologies Corp.
NEW YORK, Oct. 19, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors concerning the proposed acquisition of the company by Endo International plc (NASDAQ: ENDP). Stockholders will receive $88.50 for each share of BioSpecifics Technologies stock that they hold. The transaction is valued at approximately $658 million and is expected to close in the fourth quarter of 2020.
Oct 19, 2020 01:14 pm ET
BIOSPECIFICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BSTC and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of BioSpecifics Technologies Corp. (NASDAQ: BSTC) breached their fiduciary duties or violated the federal...
Oct 19, 2020 10:04 am ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BioSpecifics Technologies Corp. Buyout
Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be...
Oct 19, 2020 07:30 am ET
BioSpecifics to be Acquired by Endo Pharmaceuticals
WILMINGTON, Del., Oct. 19, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated equity value of approximately $658.0 million ($540.0 million in enterprise value net of cash on hand), or $88.50 per share in cash. The transaction was unanimously approved by both BioSpecifics' and Endo's Boards of Directors and is anticipated to close during the fourth quarter of 2020.
Oct 19, 2020 07:30 am ET
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
-- Endo to acquire BioSpecifics in an accretive all-cash transaction --
Oct 19, 2020 07:30 am ET
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
-- Endo to acquire BioSpecifics in an accretive all-cash transaction --
Oct 09, 2020 07:30 am ET
Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)
DUBLIN, Oct. 9, 2020 /CNW/ -- Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured during the American Society for Dermatologic Surgery's Annual Meeting (ASDS). These data will be highlighted in three posters and two oral presentations during the virtual meeting taking place October 9 – 11, 2020.
Oct 07, 2020 05:00 pm ET
Endo to Announce Third Quarter 2020 Financial Results
DUBLIN, Oct. 7, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2020 financial results on November 5, 2020 after the market closes and members of its senior management team will host a conference call and webcast on November 6, 2020 at 7:30am EST.
Oct 06, 2020 02:34 pm ET
Endo Releases First Environmental, Social and Governance Report
DUBLIN, Oct. 6, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced the release of its first Environmental, Social and Governance (ESG) report, titled 2019 Corporate Responsibility Report: Helping Everyone We Serve Live Their Best Life. It summarizes the Company's current efforts to responsibly serve customers and patients, team members and other stakeholders, and it provides a starting point to build and further strengthen Endo's ESG programs and practices.
Oct 01, 2020 05:38 pm ET
Endo Begins Shipment of Generic Kuvan® Tablets and Powder for Oral Solution (sapropterin dihydrochloride)
DUBLIN, Oct. 1, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiary, Par Pharmaceutical, Inc. (Par), has begun shipping sapropterin dihydrochloride tablets, 100 mg, and powder for oral solution, 100 mg and 500 mg, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par's sapropterin dihydrochloride tablets and powder for oral solution are the generic version of Kuvan® tablets and powder for oral solution and are the first, and currently the only, generic versions available.
Sep 25, 2020 07:00 am ET
Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate
DUBLIN, Sept. 25, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiary, Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax' COVID-19 vaccine candidate.
Sep 24, 2020 07:00 am ET
Endo to Present Qwo™ (collagenase clostridium histolyticum-aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)
DUBLIN, Sept. 24, 2020 /CNW/ -- Endo International plc (NASDAQ:ENDP) today announced that it will present data relevant to the use of Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women during Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS). This data will be highlighted in two oral presentations during the virtual VCS symposium taking place September 24 – 27, 2020.
Sep 08, 2020 05:30 pm ET
Endo to Participate at Citi 15th Annual BioPharma Virtual Conference
DUBLIN, Sept. 8, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that it will participate in the Citi 15th Annual BioPharma Virtual Conference being held September 8-10, 2020. Members of management will host virtual meetings at the Conference on September 10, 2020.
Sep 08, 2020 04:02 pm ET
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who has served as a member of the Company’s Board of Directors since January 2020, will succeed David G....
Aug 21, 2020 08:30 pm ET
Endo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer
DUBLIN, Aug. 21, 2020 /CNW/ -- Endo International plc (the "Company") (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the "Offer") by its wholly owned subsidiary Endo Finance LLC ("Endo Finance") for any and all of its outstanding 5.75% Senior Notes due 2022 (the "Notes"), which expired at 5:00 p.m., New York City time, on August 21, 2020 (the "Expiration Time").
Aug 17, 2020 02:55 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Endo International plc (ENDP)
The Law Offices of Frank R. Cruz reminds investors of the upcoming August 18, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Endo International plc ("Endo" or "the Company") (NASDAQ:
Aug 17, 2020 08:00 am ET
Endo International plc Commences Tender Offer For Any And All Of Its Outstanding 5.75% Senior Notes Due 2022
DUBLIN, Aug. 17, 2020 /CNW/ -- Endo International plc (the "Company" or "Endo") (NASDAQ: ENDP) announced today that Endo Finance LLC ("Endo Finance"), a wholly-owned subsidiary of the Company, has commenced a cash tender offer for any and all of its outstanding 5.75% Senior Notes due 2022 (CUSIP No. 29271L AA2; U2918V AA3) (the "Notes"), on the terms and subject to the conditions set forth in the Offer to Purchase, dated as of the date hereof (the "Offer to Purchase") and the related Notice of Guaranteed Delivery attached to the Offer to Purchase (the "Notice of Guaranteed Delivery"). As of
Aug 15, 2020 06:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDP
Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc (“Endo” or the “Company”) (NASDAQ: ENDP) and certain of its officers. The class action, filed in United States District Court for the District of...
Aug 13, 2020 01:00 pm ET
ENDP DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Endo International plc and Lead Plaintiff Deadline: August 18, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) and certain of its officers, on behalf of shareholders...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.